Literature DB >> 24672120

Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses.

Steven R Feldman1.   

Abstract

BACKGROUND: Topical corticosteroids have long been the cornerstone in thetreatment of steroid-responsive dermatoses. Despite the effectiveness of these formulations, there is a misperception that drugs delivered via ointments are more potent than those delivered via other vehicles. Potency, however, is a complex function of the physical and chemical properties of both the active ingredient and its vehicle. Studies have determined that newer vehicles (eg, lotions), particularly those in the super-high-potency class, not only heighten the ability of the active ingredient to penetrate skin but also are preferred by patients over ointments and creams.
OBJECTIVE: This review of the literature investigates the effectiveness andtolerability of a high-potency corticosteroid lotion compared with cream or emollient cream formulations in treating moderate to severe plaque-type psoriasis and atopic dermatitis.
METHODS: A literature search was conducted of US and international published clinical trials (1975 to November 2004) comparing all potencies of topical corticosteroid cream and lotion formulations using MEDLINE and the Web sites of individual dermatologic journals. No specific study designs were excluded from this search. Search terms included corticosteroid-responsive dermatoses, creams versus lotions, topical corticosteroid clinical trials, plaque-type psoriasis, atopic dermatitis, clobetasol propionate, drug bioavailability, Class I topical agents, and vasoconstriction. The primary diagnoses were moderate to severe plaque-type psoriasis and atopic dermatitis. Two unpublished clinical investigations comparing clobetasol propionate lotion 0.05% with clobetasol propionate cream 0.05% and emollient cream 0.05% in a total of 421 patients were also included.
RESULTS: In the 20 published and 2 unpublished trials identified and reviewed, the response rates were comparable between the lotion and cream formulations. In addition, in a psoriasis study, clobetasol lotion received significantly better cosmetic-acceptability ratings compared with clobetasol cream (P < 0.05).
CONCLUSION: In the studies reviewed, the effectiveness and tolerability of clobetasollotion were comparable to those of clobetasol cream and emollient cream in studies in adults with moderate to severe psoriasis or atopic dermatitis.

Entities:  

Keywords:  Class I agents; anti-inflammatory; atopic dermatitis; clobetasol propionate; cosmetic acceptability; duration of response; efficacy; plaque-type psoriasis; potency; safety; topical corticosteroids; vasoconstriction; vehicle

Year:  2005        PMID: 24672120      PMCID: PMC3964525          DOI: 10.1016/j.curtheres.2005.06.010

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  29 in total

Review 1.  The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments.

Authors:  R B Stoughton
Journal:  Int J Dermatol       Date:  1992-10       Impact factor: 2.736

2.  Twice-weekly topical corticosteroid therapy may reduce atopic dermatitis relapses.

Authors:  Hywel C Williams
Journal:  Arch Dermatol       Date:  2004-09

Review 3.  Percutaneous absorption of drugs.

Authors:  R B Stoughton
Journal:  Annu Rev Pharmacol Toxicol       Date:  1989       Impact factor: 13.820

4.  Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis.

Authors:  S J Yawalkar; L Schwerzmann
Journal:  J Am Acad Dermatol       Date:  1991-12       Impact factor: 11.527

5.  A comparison of betamethasone benzoate gel and betamethasone valerate cream.

Authors:  L C Parish; J A Witkowski
Journal:  Cutis       Date:  1976-05

6.  Relation of application time to bioactivity of a potent topical glucocorticoid formulation.

Authors:  R B Stoughton; K Wullich
Journal:  J Am Acad Dermatol       Date:  1990-06       Impact factor: 11.527

Review 7.  Topical corticosteroids in clinical practice: focus on fluticasone propionate.

Authors:  D J Piacquadio
Journal:  Cutis       Date:  1996-02

8.  Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group.

Authors:  L Molin; T P Cutler; I Helander; B Nyfors; N Downes
Journal:  Br J Dermatol       Date:  1997-01       Impact factor: 9.302

9.  Diprolene cream in the treatment of severe or resistant corticosteroid-responsive dermatoses.

Authors:  J C Lodolo
Journal:  J Int Med Res       Date:  1984       Impact factor: 1.671

10.  Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment.

Authors:  S S Bleehen; A C Chu; I Hamann; C Holden; J A Hunter; R Marks
Journal:  Br J Dermatol       Date:  1995-10       Impact factor: 9.302

View more
  1 in total

Review 1.  Safety of topical corticosteroids in atopic eczema: an umbrella review.

Authors:  Emma Axon; Joanne R Chalmers; Miriam Santer; Matthew J Ridd; Sandra Lawton; Sinead M Langan; Douglas J C Grindlay; Ingrid Muller; Amanda Roberts; Amina Ahmed; Hywel C Williams; Kim S Thomas
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.